Years later, when I did some consulting on the side, I had a similar experience. I recall one particular meeting when I felt some synergy with a department head at a gas company.
Investment services company, Xplore Wealth Limited (ASX: XPL) today downgraded its FY2019 EBITDA guidance to $3 million – $4 million, lower than the initial guidance of $7 million – $8.5 million as announced in March 2019.
The massive decline in the company’s expectation underscores the revenue shortfall resulting partly from delays in new product launches; synergy benefits not realised yet; software development costs expensed which was previously forecasted to be capitalised and investments into growth initiatives.
Baes in New South Wales, the company provides services to brokers, wealth managers and financial advisory firms, offering technology solution, administration, managed discretionary accounts and Investment & Superannuation Wrap.
Xplore Wealth Ltd acquired Linear Financial holdings to access an extensive suite of products and services. The acquisition resulted in synergy benefits of $3.5 million out of which benefits worth $2.4 million have successfully realised. The remaining synergy of $1.1 million has been reportedly delayed due to the migration of the service providers not yet occurred.
Revenues earned by due diligence and research fees are due to fund managers. Revenues are expected to realise before the end of the financial year, and the amount is expected to be $0.9 million.
The company stated that the receipt of the GST refunds ($1.9m and the $1.6m) is reliant on a Responsible Entity of the Linear Managed Account lodging the application for the refund with the ATO. It expects the registration and the application to follow for the refund to commence this week. But $1.6 million amount from tax refunds is not included in the current revised guidance as it pertains to previous financial years. However, the directors of the company are likely that monies will be recoverable in the financial year 2019.
New product launch delays have resulted in an expected revenue shortfall of $1.7 million. The company is committed to developing employees and growth initiatives, recently invested AUD 500k for skills upgrade.
Based on the above changes, XPL has revised its guidance to the range of $3- 4 million after adjusting for the above stated changes in the initial guidance. The deductions include revenue shortfall of $1.7 million, unrealised synergies of $1.1 million, investments into growth initiatives of $0.5 million and software development cost of $0.3 million recorded as expense.
Xplore wealth is adapting to numerous growth strategies and initiatives that aim to improve profitability. The successful rebranding and relaunching of the group well positions the company for active sales campaign and driving revenue growth. The directors expect to appoint a CEO in a near-term to direct the organisation and drive improved performance.
Peter Brook, Chairman of Xplore Wealth, highlighted the progress made the company over the past year in rebranding and repositioning with extensive product suite; however, he also mentioned the disappointment to deliver revised EBITDA guidance. Xplore has an exciting future with new product development, scalable technology and upgraded capabilities.
Mr Brook added that Linear acquisition has been a positive development for the Group expanding our opportunity set.
XPL stock plunged by 16.667% to last trade at $0.110 on 8 May 2019. The 52-week high and low of the stock stands at $0.255 and $0.095, respectively. Over the past 12 months, the stock has gone down by 44.19% including a negative YTD performance of 25%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
People prefer a dividend stock in their portfolio as it possesses the feature of compounding. Compounding means that the earning which is generated through these dividend stock will get reinvested and will eventually create earnings from earning. More precisely, the dividend generated from these dividend stock will get reinvested to buy another set of a share of the dividend stock which results in giving a higher dividend.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’sThose phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.
Innovate UK, the operating name of the UK Technology Strategy Board, has awarded two AI companies more than £300,000 ($387,600) and will co-invest an additional £130,000 ($168,000) from the grant’s funding pot of £20m ($25.8m). The money will be used by the companies to deliver a partnership project entitled: “Chemeia: A synergistic AI integrated architecture for augmenting high value dark-data”.
The two businesses, Manchester-based Biorelate and Cambridge-based Intellegens, announced their success in the third round of Innovate UK’s open grant funding competition.
Intellegens has developed Alchemite, which uses AI to predict ranked unknown data-points and uncertainties, while Biorelate is in the process of developing text analytics and data mining cloud-based platform Galactic AI.
Project Chemeia (pronounced Chem-ee-a) will test the potential for combining the capabilities of both company’s platforms to produce up-to-date, comprehensive and reliable datasets for high-value R&D work.
While current AI methods for curating scientific experimental data can be slow and prone to leaving gaps in the information they produce, the project will attempt to improve data curation techniques to help firms garnering data from in-house experiments and information from external sources to integrate results for further analysis.
Ben Pellegrini, CEO and co-founder of Intellegens, remarked: “Independently, our AI technologies are proven; together they have the potential to take the pain out of data curation.
“We work with sparse data, using our deep-learning algorithm to make accurate predictions in datasets that are as little as 0.05% complete. With the funding granted by Innovate UK we’ll be able to exploit the synergies between these two approaches and see if it is possible to create a powerful new approach that can transform data curation.”
Biorelate CEO and founder Dr Daniel Jamieson added: “Adequate data curation underpins so much of the future success of research and development in science and Biorelate is continually investing in innovative ways to improve this.
“What really excites me about this project is the prospect of bringing two completely different, game-changing technologies together to achieve something entirely novel.”
Innovate UK has a remit to support businesses in developing and realizing the potential of new ideas, which it does by connecting businesses to partners, customers and investors, as well as by providing funding.
Vanguard Group Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 5.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,025,593 shares of the biopharmaceutical company’s stock after purchasing an additional 1,224,873 shares during the quarter. Vanguard Group Inc. owned about 8.88% of Synergy Pharmaceuticals worth $37,444,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Synergy Pharmaceuticals by 272.9% during the second quarter. Bank of America Corp DE now owns 243,363 shares of the biopharmaceutical company’s stock valued at $423,000 after buying an additional 384,085 shares during the period. Chicago Equity Partners LLC lifted its holdings in Synergy Pharmaceuticals by 153.5% in the third quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 286,135 shares during the period. Nexthera Capital LP bought a new position in shares of Synergy Pharmaceuticals during the third quarter valued at approximately $1,269,000. Hikari Power Ltd increased its stake in shares of Synergy Pharmaceuticals by 8.7% during the third quarter. Hikari Power Ltd now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $4,250,000 after purchasing an additional 200,000 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Synergy Pharmaceuticals by 2.2% during the second quarter. BlackRock Inc. now owns 21,732,054 shares of the biopharmaceutical company’s stock valued at $37,815,000 after purchasing an additional 464,195 shares in the last quarter. 37.22% of the stock is currently owned by hedge funds and other institutional investors.
SGYP has been the subject of a number of analyst reports. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, October 26th. Canaccord Genuity downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $5.33.
Shares of SGYP traded down $0.01 on Tuesday, hitting $0.28. 678,439 shares of the stock traded hands, compared to its average volume of 14,718,365. The company has a market capitalization of $68.93 million, a P/E ratio of -0.28 and a beta of 4.94. Synergy Pharmaceuticals Inc has a one year low of $0.07 and a one year high of $2.26.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Featured Story: SEC Filing
Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
Acing The Last Lap of Digital Transformation
“If you have the right systems and process, a small number of talented individuals can have a big impact on a company’s digital transformation journey”, explains Infosys’ Corey Glickman. Amplifying is all about creating select high impact programs that will push the envelope for digital transformation in a big way.
Collaborating with suitable partners to boost the digital transformation. There are several advantages to partnering as elucidated in the report. However, there is a great amount of synergy required between the cultures and shared goals of both the parties to be able to achieve the success.
IT Leaders Must Become Digital Change Advocates
Finally, Digital Transformation can succeed only when it is regarded as a holistic, organization-wide phenomenon. Hence its success depend greatly on the ability of the IT leaders to step out of their comfort zones and work across boundaries and functions to lend a cohesive vision.